抗TGF-β Receptor Ⅲ抗体(Anti-TGF-β Receptor Ⅲ, Human, Goat-Poly antibody)

• 価格
• Product Details
• Applications and Data
• Related Product & Information
• Citations

価格

目次に戻る

Product Details

Species Reactivity	Human
Label	Unconjugated
Immunogen	Mouse myeloma cell line NS0-derived recombinant human TGF‑ beta  RIIIGly21-Asp781Accession # AAA67061
Source	Polyclonal Goat IgG
Purification	Antigen Affinity-purified
Specificity	Detects human TGF-beta  RIII in direct ELISAs and Western blots. In direct ELISAs, approximately 25% cross-reactivity with recombinant mouse (rm) TGF-beta  RIII is observed, and less than 1% cross-reactivity with recombinant human (rh) TGF-beta  RI, rhTGF-beta  RII, rhTGF-beta  RIIB, and rmTGF-beta  RI  is observed.

目次に戻る

Applications and Data

	Recommended Concentration	Sample
Western Blot	0.1 µg/mL	Recombinant Human TGF-beta  RIII (Catalog # 242-R3)
Flow Cytometry	2.5 µg/106 cells	See below
CyTOF-ready	Ready to be labeled using established conjugation methods. No BSA or other carrier proteins that could interfere with conjugation.

Flow Cytometry
	Detection of TGF‑ beta  RIII in PC‑3 Human Cell Line by Flow Cytometry. PC‑3 human prostate cancer cell line was stained with Goat Anti-Human TGF‑ beta  RIII Antigen Affinity‑purified Polyclonal Antibody (Catalog # AF‑242‑PB, filled histogram) or isotype control antibody (Catalog # AB-108-C, open histogram), followed by Fluorescein-conjugated Anti-Goat IgG Secondary Antibody (Catalog # F0109).

目次に戻る

Related Product & Information

Long Name	Transforming Growth Factor beta Receptor III
Background	TGF-beta RIII
background_content	Background: TGF-beta RIII Most cell types express three sizes of receptors for TGF-beta. These are designated Type I (53 kDa), Type II (70-85 kDa), and Type III (250-350 kDa). The Type I receptor is a membrane-bound serine/threonine kinase that apparently requires the presence of the Type II receptor to bind TGF-beta. The Type II receptor is also a membrane-bound serine/threonine kinase that binds TGF-beta 1 and TGF-beta 3 with high affinity and TGF-beta 2 with a much lower affinity. The Type I and Type II receptors together form a heterodimeric signaling complex that is essential for the transduction of the anti-proliferative signals of TGF-beta. The Type III receptor is a transmembrane proteoglycan with a large extracellular domain and a 43 amino acid residue cytoplasmic domain. The cytoplasmic domain of the Type III receptor lacks an obvious signaling motif and the receptor may not be involved directly in signal transduction. The Type III receptor binds TGF-beta 2 with the highest affinity. Other TGF-beta isoforms also bind the Type III receptor, but with lower affinities. Cellular responsiveness to TGF-beta 2 appears to be dependent on the presence of the Type III receptor which can interact with the signaling receptor complex. In addition to the transmembrane Type III receptor, a soluble form of the receptor is secreted by some cell types. The physiological role of this soluble receptor remains to be determined. The recombinant TGF-beta soluble receptor Type III binds the TGF-beta isoforms differentially in solution and exhibits TGF-beta antagonistic activities in vitro.

目次に戻る

Citations

1. Altering the Proteoglycan State of Transforming Growth Factor ? Type III Receptor (T?RIII)/Betaglycan Modulates Canonical Wnt/?-Catenin Signaling
   Authors: Karthikeyan Mythreye
   J. Biol. Chem., 2016;291(49):25716-25728.
   Application: IP


2. TWIST1-Induced miR-424 Reversibly Drives Mesenchymal Programming while Inhibiting Tumor Initiation.
   Authors: Drasin D, Guarnieri A, Neelakantan D, Kim J, Cabrera J, Wang C, Zaberezhnyy V, Gasparini P, Cascione L, Huebner K, Tan A, Ford H
   Cancer Res, 2015;75(9):1908-21.
   Species: Human
   Sample Type: Whole Cells
   Application: Flow


3. Molecular signatures and transcriptional regulatory networks of human immature decidual NK and mature peripheral NK cells.
   Authors: Wang F, Zhou Y, Fu B, Wu Y, Zhang R, Sun R, Tian Z, Wei H
   Eur J Immunol, 2014;44(9):2771-84.
   Species: Human
   Sample Type: Whole Cells
   Application: Flow


4. Expression of growth factors and growth factor receptor in non-healing and healing ischaemic ulceration.
   Authors: Murphy MO, Ghosh J, Fulford P, Khwaja N, Halka AT, Carter A, Turner NJ, Walker MG
   Eur J Vasc Endovasc Surg, 2006;31(5):516-22.
   Species: Human
   Sample Type: Whole Tissue
   Application: IHC


5. Inhibin alpha-subunit and the inhibin coreceptor betaglycan are downregulated in endometrial carcinoma.
   Authors: Florio P, Ciarmela P, Reis FM, Toti P, Galleri L, Santopietro R, Tiso E, Tosi P, Petraglia F
   Eur. J. Endocrinol., 2005;152(2):277-84.
   Species: Human
   Sample Type: Whole Tissue
   Application: IHC Paraffin-embedded


6. Extracellular domain of TGFbeta type III receptor inhibits angiogenesis and tumor growth in human cancer cells.
   Authors: Bandyopadhyay A, Zhu Y, Malik SN, Kreisberg J, Brattain MG, Sprague EA, Luo J, Lopez-Casillas F, Sun LZ
   Oncogene, 2002;21(22):3541-51.
   Species: Human
   Sample Type: Cell Culture Supernates
   Application: ELISA Development


7. TGF-beta1 regulates TGF-beta1 and FGF-2 mRNA expression during fibroblast wound healing.
   Authors: Song QH, Klepeis VE, Trinkaus-Randall V
   MP, Mol. Pathol., 2002;55(3):164-76.
   Species: Rabbit
   Sample Type: Whole Tissue
   Application: IHC


8. Transforming growth factor-beta1 regulation of growth zone chondrocytes is mediated by multiple interacting pathways.
   Authors: Rosado E, Schwartz Z, Sylvia VL, Dean DD, Boyan BD
   Biochim. Biophys. Acta, 2002;1590(1):1-15.
   Species: Rat
   Sample Type: Whole Cells
   Application: Neut

目次に戻る